Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor Necrosis Factor-Alpha Converting Enzyme (ADAM17)
- Target
- ADAM17
- Molecular classification
- Metalloprotease, Type I transmembrane protein, Enzyme
01
Overview
ADAM17, also known as TACE, is a zinc-dependent metalloprotease responsible for the ectodomain shedding of numerous cell surface proteins, including TNF-alpha, interleukin 6 receptor, EGFR ligands and Notch receptors. This proteolytic activity plays critical roles in inflammation, immune responses, cell signaling, development, and tissue remodeling. Dysregulation of ADAM17 is implicated in several diseases, including chronic inflammatory conditions and cancer, making it a therapeutic target. Its activity is tightly regulated and its inhibition can have diverse biological effects.
- Other names
- TACECD156q
02
Mechanism of action
Inhibition of ADAM17 proteolytic activity.
03
Biological functions
Ectodomain sheddingCytokine processingReceptor processingInflammatory responseCell proliferationDevelopmentTissue remodelingImmune response
04
Disease associations
Chronic inflammatory diseasesRheumatoid arthritisCancerPsoriasisDevelopmental defects
05
Safety considerations
Potential for off-target effects due to broad substrate specificity.Developmental defects in knockout models suggest caution when inhibiting during pregnancy.
Beyond the preview
Go deeper on Tumor Necrosis Factor-Alpha Converting Enzyme (ADAM17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor Necrosis Factor-Alpha Converting Enzyme (ADAM17).